Market Overview

UPDATE: Jefferies Raises PT on Bristol-Myers Squibb on Positive Outlook

Share:
Related BMY
Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever
Bristol-Myers Stock May Have Exhausted Its Upside For Now
Sabal Trust CO Buys United Parcel Service Inc, Bristol-Myers Squibb Company, Hanesbrands Inc, ... (GuruFocus)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), and raised the price target from $41.00 to $45.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Bristol-Myers Squibb Co. closed on Tuesday at $40.83.

Latest Ratings for BMY

DateFirmActionFromTo
Oct 2017CitigroupMaintainsBuy
Oct 2017JefferiesDowngradesBuyHold
Oct 2017BarclaysMaintainsEqual-Weight

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...